192 related articles for article (PubMed ID: 24195644)
1. Immunogenicity and therapeutic efficacy of a dual-component genetic cancer vaccine cotargeting carcinoembryonic antigen and HER2/neu in preclinical models.
Aurisicchio L; Peruzzi D; Koo G; Wei WZ; La Monica N; Ciliberto G
Hum Gene Ther; 2014 Feb; 25(2):121-31. PubMed ID: 24195644
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors.
Diaz CM; Chiappori A; Aurisicchio L; Bagchi A; Clark J; Dubey S; Fridman A; Fabregas JC; Marshall J; Scarselli E; La Monica N; Ciliberto G; Montero AJ
J Transl Med; 2013 Mar; 11():62. PubMed ID: 23497415
[TBL] [Abstract][Full Text] [Related]
3. Vectors encoding carcinoembryonic antigen fused to the B subunit of heat-labile enterotoxin elicit antigen-specific immune responses and antitumor effects.
Facciabene A; Aurisicchio L; Elia L; Palombo F; Mennuni C; Ciliberto G; La Monica N
Vaccine; 2007 Dec; 26(1):47-58. PubMed ID: 18055074
[TBL] [Abstract][Full Text] [Related]
4. Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice.
Xie Y; Wu J; Xu A; Ahmeqd S; Sami A; Chibbar R; Freywald A; Zheng C; Xiang J
Vaccine; 2018 Mar; 36(11):1414-1422. PubMed ID: 29415817
[TBL] [Abstract][Full Text] [Related]
5. Increasing vaccine potency through exosome antigen targeting.
Hartman ZC; Wei J; Glass OK; Guo H; Lei G; Yang XY; Osada T; Hobeika A; Delcayre A; Le Pecq JB; Morse MA; Clay TM; Lyerly HK
Vaccine; 2011 Nov; 29(50):9361-7. PubMed ID: 22001882
[TBL] [Abstract][Full Text] [Related]
6. Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector.
Gallo P; Dharmapuri S; Nuzzo M; Maldini D; Iezzi M; Cavallo F; Musiani P; Forni G; Monaci P
Int J Cancer; 2005 Jan; 113(1):67-77. PubMed ID: 15386429
[TBL] [Abstract][Full Text] [Related]
7. A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses.
Conforti A; Peruzzi D; Giannetti P; Biondo A; Ciliberto G; La Monica N; Aurisicchio L
J Immunother; 2009 Sep; 32(7):744-54. PubMed ID: 19561534
[TBL] [Abstract][Full Text] [Related]
8. An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity.
Hartman ZC; Wei J; Osada T; Glass O; Lei G; Yang XY; Peplinski S; Kim DW; Xia W; Spector N; Marks J; Barry W; Hobeika A; Devi G; Amalfitano A; Morse MA; Lyerly HK; Clay TM
Clin Cancer Res; 2010 Mar; 16(5):1466-77. PubMed ID: 20179231
[TBL] [Abstract][Full Text] [Related]
9. Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA.
Mennuni C; Calvaruso F; Facciabene A; Aurisicchio L; Storto M; Scarselli E; Ciliberto G; La Monica N
Int J Cancer; 2005 Nov; 117(3):444-55. PubMed ID: 15906358
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of recombinant adenovirus vectors and adjuvanted protein as a heterologous prime-boost strategy using HER2 as a model antigen.
Haq K; Jia Y; Elahi SM; MacLean S; Akache B; Gurnani K; Chattopadhyay A; Nazemi-Moghaddam N; Gilbert R; McCluskie MJ; Weeratna RD
Vaccine; 2019 Nov; 37(47):7029-7040. PubMed ID: 31506193
[TBL] [Abstract][Full Text] [Related]
11. Strengthened tumor antigen immune recognition by inclusion of a recombinant Eimeria antigen in therapeutic cancer vaccination.
Quiroga D; Aldhamen YA; Appledorn DM; Godbehere S; Amalfitano A
Cancer Immunol Immunother; 2015 Apr; 64(4):479-91. PubMed ID: 25655760
[TBL] [Abstract][Full Text] [Related]
12. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
13. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
[TBL] [Abstract][Full Text] [Related]
14. A novel chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines.
Peruzzi D; Dharmapuri S; Cirillo A; Bruni BE; Nicosia A; Cortese R; Colloca S; Ciliberto G; La Monica N; Aurisicchio L
Vaccine; 2009 Feb; 27(9):1293-300. PubMed ID: 19162112
[TBL] [Abstract][Full Text] [Related]
15. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
Aarts WM; Schlom J; Hodge JW
Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant activity of GP96 C-terminal domain towards Her2/neu DNA vaccine is fusion direction-dependent.
Pakravan N; Hashemi SM; Hassan ZM
Cell Stress Chaperones; 2011 Jan; 16(1):41-8. PubMed ID: 20730610
[TBL] [Abstract][Full Text] [Related]
17. DNA and adenoviral vectors encoding carcinoembryonic antigen fused to immunoenhancing sequences augment antigen-specific immune response and confer tumor protection.
Facciabene A; Aurisicchio L; Elia L; Palombo F; Mennuni C; Ciliberto G; La Monica N
Hum Gene Ther; 2006 Jan; 17(1):81-92. PubMed ID: 16409127
[TBL] [Abstract][Full Text] [Related]
18. A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu-Expressing Tumor in HLA-A2 Transgenic Mice.
Tran T; Diniz MO; Dransart E; Gey A; Merillon N; Lone YC; Godefroy S; Sibley C; Ferreira LC; Medioni J; Oudard S; Johannes L; Tartour E
Clin Cancer Res; 2016 Aug; 22(16):4133-44. PubMed ID: 27006496
[TBL] [Abstract][Full Text] [Related]
19. Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.
Wang X; Wang JP; Rao XM; Price JE; Zhou HS; Lachman LB
Breast Cancer Res; 2005; 7(5):R580-8. PubMed ID: 16168101
[TBL] [Abstract][Full Text] [Related]
20. CCL19 as an adjuvant for intradermal gene gun immunization in a Her2/neu mouse tumor model: improved vaccine efficacy and a role for B cells as APC.
Nguyen-Hoai T; Hohn O; Vu MD; Baldenhofer G; Sayed Ahmed MS; Dörken B; Norley S; Lipp M; Pezzutto A; Westermann J
Cancer Gene Ther; 2012 Dec; 19(12):880-7. PubMed ID: 23099886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
